HeartBeam (NASDAQ: BEAT) was among the medical device companies featured in a Jan. 8 report by Modern Healthcare that outlined recent FDA clearances and approvals across the sector. The company’s 12-lead electrocardiogram synthesis software, cleared Dec. 8, converts heart signal data captured from three dimensions using a portable, non-invasive recorder into a standard 12-lead ECG format suitable for remote clinical review, enabling arrhythmia assessment.
This clearance marks a significant advancement in remote cardiac monitoring, as it allows physicians to evaluate patients’ cardiac health outside traditional clinical settings. The technology leverages a three-dimensional signal capture approach, distinguishing it from conventional ECG devices. HeartBeam’s intellectual property portfolio, which includes 82 global patent publications across 15 patent families, supports this architecture and has been recognized in PatentVest’s “Total Cardiac Intelligence” report, where the company ranked second worldwide in 12-lead ECG innovation, trailing only GE Healthcare. The recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics underscores the strength of HeartBeam’s innovation in next-generation remote cardiac monitoring, according to an InvestorBrandNetwork report.
The implications of this technology are far-reaching. By enabling cable-free, portable ECG data collection and synthesis, HeartBeam aims to redefine cardiac health management by allowing patients to be monitored anywhere, potentially improving early detection of arrhythmias and reducing the need for in-person visits. This aligns with the broader trend toward decentralized healthcare and remote patient monitoring. For more details on the technology, visit HeartBeam’s Portable ECG Technology page.
HeartBeam, Inc. is a medical technology company focused on transforming cardiac condition detection and monitoring. Its platform is designed to deliver actionable heart intelligence through portable devices, with the goal of helping physicians identify cardiac health trends and acute conditions, directing patients to appropriate care. The company holds over 20 issued patents and received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024, followed by the 12-Lead ECG synthesis software clearance in December 2025. Additional information is available at HeartBeam.com.
Forward-looking statements in this release involve risks and uncertainties as detailed in the company’s SEC filings. For the latest news and updates, visit the company’s newsroom at https://ibn.fm/BEAT.
